Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated

Journal of Investigative Dermatology

Volumn 119, Issue 4, 2002, Pages 876-887

  Rappersberger, Klemens ^a   Komar, Michael ^a   Ebelin, Marie Eve ^b   Scott, Graham ^b   Burtin, Pascale ^b   Greig, Gerard ^b   Kehren, Jeanne ^b   Chibout, Salah Dine ^b   Cordier, Andre ^b   Holter, Wolfgang ^c   Richter, Leo ^a   Oberbauer, Rainer ^d   Stuetz, Anton ^e   Wolff, Klaus ^a  

^a Division of General Dermatology   (Austria)

^b NOVARTIS PHARMA AG   (Switzerland)

^c ST ANNA CHILDREN S HOSPITAL   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e Novartis Research Institute   (Austria)

Author keywords

Ascomycin; Pharmacogenomics; Pharmacokinetics; Pimecrolimus; Psoriasis

Indexed keywords

PIMECROLIMUS; PLACEBO;

ADULT; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DOWN REGULATION; DRUG EFFICACY; DRUG TOLERANCE; GENE EXPRESSION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOLOGY; INFLAMMATION; MALE; PHARMACOGENOMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PSORIASIS; SKIN INFLAMMATION; STEADY STATE;

EID: 19244366008     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.2002.00694.x     Document Type: Article

References (32)

1. Bachelez H, Flageul B, Dubertret L, et al: Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4. J Autoimmun 11:53-62, 1998
2. Baker B, Fry L: The immunology of psoriasis. Br J Dermatol 126:1-9, 1992
3. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomized trial. Lancet 357:1842-1847, 2001
4. Ellis CN, Krueger GG: Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 345:248-255, 2001
5. Ellis CN, Gorsulowsky DC, Hamilton TA: Cyclosporin improves psoriasis in a double-blind study. J Am Acad Dermatol 256:3110-3116, 1986
6. 389 IL-2) suggest a primary immune but not keratinocyte pathogenic basis. Nature Med 1:442-447, 1995
7. Gottlieb A, Krueger JG, Bright R, et al: Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 42:428-435, 2000a
8. Gottlieb AB, Lebwohl M, Shirin S, Sherr A, Gilleaudeau P, Singer G: Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: Results of a pilot, multicenter, multiple-dose, placebo-controlled study. J Am Acad Dermatol 43:595-604, 2000b
9. Grassberger M, Baumruker T, Enz A, et al: A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: In vitro pharmacology. Br J Dermatol 141:264-273, 1999
10. Harper J, Green A, Scott G, Gruendl E, Dorobek B, Cardno M, Burtin P: First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol 144:781-789, 2001
11. Hönigsmann H, Fitzpatrick TB, Pathak MA, Wolff K: Oral photochemotherapy with psoralens and UVA (PUVA): Principles and practice. In: Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF (eds). Dermatology in General Medicine. New York: McGraw-Hill, 1994, pp 1728-1754
12. Jegasothy BV, Ackerman CD, Todo S, Fung JJ, Abu-Elmagd K, Starzl TE: Tacrolimus (FK506): A new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol 128:781-785, 1992
13. Krueger JG, Walters IB, Miyazawa M, et al: Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by admnistration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol 43:448-458, 2000
14. Lebwohl M, Ellis C, Gottlieb A, et al: Cyclosporine consensus conference: With emphasis on the treatment of psoriasis. J Am Acad Dermatol 39:464-475, 1998
15. Linden KG, Weinstein GD: Use of methotrexate in psoriasis. Dermatol Ther 11:52-59, 1999
16. Meingassner JG, Fahrngruber H, Barandi A: SDZASM981, in contrast to CyA and FK 506, does not suppress the primary immune response in murine allergic contact dermatitis (abstract). J Invest Dermatol 114:832, 2000
17. Meingassner JG, Grassberger M, Fahrngruber H, Moore HD, Schuurman H, Stuetz A: A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: In vivo pharmacology. Br J Dermatol 137:568-576, 1997
18. Mihatsch MJ, Wolff K: Consensus conference on cyclosporin A for psoriasis. Br J Dermatol 126:621-623, 1992
19. Morel P, Revillard JP, Nicolas JF, Wijdenses J, Rizova H, Thivolet J: Anti-CD4 monoclonal antibody therapy in severe psoriasis. J Autoimmun 5:465-477, 1992
20. Mrowietz U, Gräber M, Brautigam M, Thurston M, Wagenaar A, Weidinger G, Christophers E: The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol 139:992-996, 1998
21. Mrowietz U, Zhu K, Christophers E: Treatment of severe psoriasis with anti-CD25 monoclonal antibodies. Arch Dermatol 136:675-676, 2000
22. Neckermann G, Bavandi A, Meingassner JG: Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981. Br J Dermatol 142:669-679, 2000
23. Nicolas JF, Chamchich N, Thivolet J, Wijdenes J, Morel P, Revillard JP: CD4 antibody treatment of severe psoriasis. Lancet 338:321, 1991
24. Oh CJ, Das KM, Gottlieb AB: Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 42:829-830, 2000
25. Owen CM, Harrison PV: Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody. Clin Exp Dermatol 25:195-197, 2000
26. Paul C, Graeber M, Stuetz A: Ascomycins, promising agents for the treatment of inflammatory skin diseases. Expert Opin Invest Drugs 9:69-77, 2000
27. Prinz J, Braun-Falco O, Meurer M: Chimeric CD4 monoclonal antibody in treatment of generalized pustular psoriasis. Lancet 338:320-321, 1991
28. Queille-Roussel C, Graeber M, Thurston M, Lachapelle JM, Decroix J, DeCuyper C, Ortonne JP: SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge. Contact Dermatitis 42:149-150, 2000
29. Stuetz A, Grassberger M, Meingassner JG: Pimecrolimus (Elidel, SDZ ASM 981)-Preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg 20:233-241, 2001
30. Van Leent EJM, Gräber M, Thurston M, Wagenaar A, Spuls PI, Bos J: Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 134:805-809, 1998
31. Weinshenker BG, Bass BH, Ebers GC, Rice GPA: Remission of psoriatic lesions with muromonab CD3 (Orthoclone OKT3) treatment. J Am Acad Dermatol 20:1132-1133, 1989
32. Wellington K, Spencer CM: Adis New Drug Profile: ASM 981. Biodrugs 74:409-416, 2000